Nanjing Leads Biolabs Wins FDA Fast Track Status for Multiple Myeloma Drug LBL-034

Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) has shared an update.

Nanjing Leads Biolabs has announced that its bispecific T-cell engager candidate LBL-034, which targets both GPRC5D and CD3 to redirect and activate T cells against GPRC5D-positive cancer cells, has received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory multiple myeloma. The designation, which follows earlier Orphan Drug status and promising preclinical and early clinical data including a high-profile presentation at the 2025 ASH conference, is expected to facilitate closer FDA interaction and potentially accelerate review timelines, strengthening the company’s position in the competitive multiple myeloma space while underscoring both the therapeutic potential of LBL-034 and the development risks that still remain for investors.

The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.

More about Nanjing Leads Biolabs Co., Ltd. Class H

Nanjing Leads Biolabs Co., Ltd. is a China-based biopharmaceutical company focused on developing innovative biologic therapies, particularly bispecific T-cell engagers, for serious cancers such as malignant plasma cell neoplasms and relapsed/refractory multiple myeloma, leveraging its proprietary LeadsBody CD3 T-cell engager platform to address unmet medical needs in oncology.

Average Trading Volume: 545,227

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$11.77B

For an in-depth examination of 9887 stock, go to TipRanks’ Overview page.